Viridian Therapeutics Net Income
| VRDN Stock | USD 33.00 0.57 1.70% |
As of the 31st of January, Viridian Therapeutics has the Risk Adjusted Performance of 0.1893, semi deviation of 1.08, and Coefficient Of Variation of 398.77. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Viridian Therapeutics, as well as the relationship between them.
Viridian Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 41.354 | Revenue | Earnings Share (3.03) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -243 M | -230.8 M | |
| Net Loss | -116.9 M | -111 M | |
| Net Loss | -243 M | -230.8 M | |
| Net Loss | (3.58) | (3.76) | |
| Net Income Per E B T | 1.16 | 1.02 |
Viridian | Net Income | Build AI portfolio with Viridian Stock |
Evaluating Viridian Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Viridian Therapeutics's fundamental strength.
Latest Viridian Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Viridian Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Viridian Therapeutics financial statement analysis. It represents the amount of money remaining after all of Viridian Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Viridian Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viridian Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (269.95 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Viridian Net Income Regression Statistics
| Arithmetic Mean | (85,777,589) | |
| Coefficient Of Variation | (115.14) | |
| Mean Deviation | 83,219,642 | |
| Median | (32,703,000) | |
| Standard Deviation | 98,765,753 | |
| Sample Variance | 9754.7T | |
| Range | 267.8M | |
| R-Value | (0.89) | |
| Mean Square Error | 2175.3T | |
| R-Squared | 0.79 | |
| Slope | (17,394,344) | |
| Total Sum of Squares | 156074.8T |
Viridian Net Income History
Other Fundumenentals of Viridian Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Viridian Therapeutics Net Income component correlations
Viridian Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Viridian Therapeutics is extremely important. It helps to project a fair market value of Viridian Stock properly, considering its historical fundamentals such as Net Income. Since Viridian Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Viridian Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Viridian Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Viridian diversify its offerings? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Viridian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.03) | Revenue Per Share | Quarterly Revenue Growth 819.581 | Return On Assets | Return On Equity |
Understanding Viridian Therapeutics requires distinguishing between market price and book value, where the latter reflects Viridian's accounting equity. The concept of intrinsic value—what Viridian Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viridian Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viridian Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Viridian Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Viridian Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Viridian Therapeutics.
| 11/02/2025 |
| 01/31/2026 |
If you would invest 0.00 in Viridian Therapeutics on November 2, 2025 and sell it all today you would earn a total of 0.00 from holding Viridian Therapeutics or generate 0.0% return on investment in Viridian Therapeutics over 90 days. Viridian Therapeutics is related to or competes with Uniqure NV, Structure Therapeutics, Edgewise Therapeutics, Galapagos, Ocular Therapeutix, Vera Therapeutics, and Arcus Biosciences. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases More
Viridian Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Viridian Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Viridian Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.48 | |||
| Information Ratio | 0.2276 | |||
| Maximum Drawdown | 15.86 | |||
| Value At Risk | (2.19) | |||
| Potential Upside | 5.57 |
Viridian Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viridian Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Viridian Therapeutics' standard deviation. In reality, there are many statistical measures that can use Viridian Therapeutics historical prices to predict the future Viridian Therapeutics' volatility.| Risk Adjusted Performance | 0.1893 | |||
| Jensen Alpha | 0.6355 | |||
| Total Risk Alpha | 0.4673 | |||
| Sortino Ratio | 0.4074 | |||
| Treynor Ratio | 1.76 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Viridian Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Viridian Therapeutics January 31, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1893 | |||
| Market Risk Adjusted Performance | 1.77 | |||
| Mean Deviation | 1.91 | |||
| Semi Deviation | 1.08 | |||
| Downside Deviation | 1.48 | |||
| Coefficient Of Variation | 398.77 | |||
| Standard Deviation | 2.65 | |||
| Variance | 7.02 | |||
| Information Ratio | 0.2276 | |||
| Jensen Alpha | 0.6355 | |||
| Total Risk Alpha | 0.4673 | |||
| Sortino Ratio | 0.4074 | |||
| Treynor Ratio | 1.76 | |||
| Maximum Drawdown | 15.86 | |||
| Value At Risk | (2.19) | |||
| Potential Upside | 5.57 | |||
| Downside Variance | 2.19 | |||
| Semi Variance | 1.17 | |||
| Expected Short fall | (2.53) | |||
| Skewness | 1.9 | |||
| Kurtosis | 5.87 |
Viridian Therapeutics Backtested Returns
Viridian Therapeutics appears to be very steady, given 3 months investment horizon. Viridian Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.23, which indicates the firm had a 0.23 % return per unit of risk over the last 3 months. By inspecting Viridian Therapeutics' technical indicators, you can evaluate if the expected return of 0.62% is justified by implied risk. Please review Viridian Therapeutics' Risk Adjusted Performance of 0.1893, coefficient of variation of 398.77, and Semi Deviation of 1.08 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Viridian Therapeutics holds a performance score of 18. The entity has a beta of 0.37, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Viridian Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Viridian Therapeutics is expected to be smaller as well. Please check Viridian Therapeutics' downside variance, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Viridian Therapeutics' existing price patterns will revert.
Auto-correlation | 0.44 |
Average predictability
Viridian Therapeutics has average predictability. Overlapping area represents the amount of predictability between Viridian Therapeutics time series from 2nd of November 2025 to 17th of December 2025 and 17th of December 2025 to 31st of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Viridian Therapeutics price movement. The serial correlation of 0.44 indicates that just about 44.0% of current Viridian Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.44 | |
| Spearman Rank Test | 0.55 | |
| Residual Average | 0.0 | |
| Price Variance | 1.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Viridian Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Viridian Therapeutics reported net income of (269.95 Million). This is 179.1% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 147.28% higher than that of the company.
Viridian Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viridian Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Viridian Therapeutics could also be used in its relative valuation, which is a method of valuing Viridian Therapeutics by comparing valuation metrics of similar companies.Viridian Therapeutics is currently under evaluation in net income category among its peers.
Viridian Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Viridian Therapeutics from analyzing Viridian Therapeutics' financial statements. These drivers represent accounts that assess Viridian Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Viridian Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 58.5M | 235.6M | 937.3M | 974.8M | 877.3M | 921.2M | |
| Enterprise Value | 13.1M | 193.9M | 786.9M | 893.0M | 803.7M | 843.9M |
Viridian Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Viridian Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Viridian Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Viridian Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Viridian Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Viridian Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Viridian Therapeutics' value.| Shares | State Street Corp | 2025-06-30 | 2.6 M | Novo A/s | 2025-06-30 | 2.4 M | Maverick Capital Ltd | 2025-06-30 | 2.3 M | Alliancebernstein L.p. | 2025-06-30 | 1.9 M | Eversept Partners, Llc | 2025-06-30 | 1.9 M | Baker Bros Advisors Lp | 2025-06-30 | 1.7 M | Geode Capital Management, Llc | 2025-06-30 | 1.7 M | Loomis, Sayles & Company Lp | 2025-06-30 | 1.3 M | Parkman Healthcare Partners Llc | 2025-06-30 | 1.3 M | Fmr Inc | 2025-06-30 | 12.2 M | Blackrock Inc | 2025-06-30 | 5.5 M |
Viridian Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (0.57) % | ||||
| Current Valuation | 2.93 B | ||||
| Shares Outstanding | 95.37 M | ||||
| Shares Owned By Insiders | 0.13 % | ||||
| Shares Owned By Institutions | 99.87 % | ||||
| Number Of Shares Shorted | 8.15 M | ||||
| Price To Book | 10.21 X | ||||
| Price To Sales | 45.26 X | ||||
| Revenue | 302 K | ||||
| Gross Profit | (247.39 M) | ||||
| EBITDA | (265.66 M) | ||||
| Net Income | (269.95 M) | ||||
| Cash And Equivalents | 161.21 M | ||||
| Cash Per Share | 5.66 X | ||||
| Total Debt | 21.09 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.77 X | ||||
| Book Value Per Share | 3.82 X | ||||
| Cash Flow From Operations | (232.32 M) | ||||
| Short Ratio | 5.23 X | ||||
| Earnings Per Share | (3.03) X | ||||
| Target Price | 41.88 | ||||
| Number Of Employees | 143 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 3.2 B | ||||
| Total Asset | 742.4 M | ||||
| Retained Earnings | (995.86 M) | ||||
| Working Capital | 690.59 M | ||||
| Net Asset | 742.4 M |
About Viridian Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viridian Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viridian Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viridian Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Viridian Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Viridian Stock
| 0.92 | APLT | Applied Therapeutics | PairCorr |
| 0.84 | LYRA | Lyra Therapeutics | PairCorr |
| 0.83 | EVGN | Evogene | PairCorr |
| 0.78 | MBIO | Mustang Bio | PairCorr |
| 0.78 | CRBP | Corbus Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.
The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viridian Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Will Biotechnology sector continue expanding? Could Viridian diversify its offerings? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Viridian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.03) | Revenue Per Share | Quarterly Revenue Growth 819.581 | Return On Assets | Return On Equity |
Understanding Viridian Therapeutics requires distinguishing between market price and book value, where the latter reflects Viridian's accounting equity. The concept of intrinsic value—what Viridian Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viridian Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viridian Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.